Real World Long-term Follow-up Experience with Yttrium-90 ibritumomab tiuxetan in Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma
Work
Year: 2022
Type: article
Abstract: IntroductionYttrium-90 ibritumomab tiuxetan [(90)Y-IT] is a CD20-targeted radio-immuno conjugate. Clinical trials of (90)Y-IT as a first-line stand-alone treatment in follicular lymphoma (FL) and/or m... more
Authors Muhamad Alhaj Moustafa, Jennifer Peterson, Bradford S. Hoppe, Jennifer Jiang, Gregory A. Wiseman +2 more
Institutions Mayo Clinic in Florida, WinnMed, Mayo Clinic in Arizona
Cites: 30
Cited by: 8
Related to: 10
FWCI: 1.802
Citation percentile (by year/subfield): 63.53
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
APC paid (est): $3,670